Orris

Generate 150mcqs for sple for doctor of pharmacy regarding pulmonology in detail

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here are 150 SPLE MCQs for Doctor of Pharmacy - Pulmonology, organized by topic with answers and brief rationales.

150 SPLE MCQs: Pulmonology for Doctor of Pharmacy

Topics covered: Asthma | COPD | Pneumonia | Tuberculosis | Pulmonary Embolism | Lung Cancer | Pulmonary Hypertension | Respiratory Pharmacology | Pulmonary Physiology | Interstitial Lung Disease | Cystic Fibrosis | Pleural Diseases | Respiratory Failure | Sleep-Disordered Breathing | Pulmonary Infections

SECTION 1: ASTHMA (Questions 1-25)

Q1. Which inhaled corticosteroid (ICS) is most commonly used as first-line controller therapy for persistent asthma?
  • A) Triamcinolone
  • B) Budesonide
  • C) Beclomethasone
  • D) Fluticasone propionate
Answer: D - Fluticasone propionate Rationale: Fluticasone propionate is widely used as a first-line ICS for persistent asthma due to its high potency, topical activity, and favorable safety profile. It is available in multiple delivery devices. (Katzung's Pharmacology)
Q2. A patient with moderate persistent asthma is poorly controlled on low-dose ICS. The GINA guidelines recommend adding which agent as the preferred step-up therapy?
  • A) Theophylline
  • B) Leukotriene receptor antagonist
  • C) Long-acting beta-2 agonist (LABA)
  • D) Oral corticosteroid
Answer: C - Long-acting beta-2 agonist (LABA) Rationale: GINA guidelines recommend adding a LABA (e.g., salmeterol, formoterol) to low-dose ICS before stepping up ICS dose. This combination provides better symptom control than increasing ICS alone. (Murray & Nadel's Respiratory Medicine)
Q3. Which of the following is the mechanism of action of montelukast in asthma?
  • A) Beta-2 adrenergic receptor agonism
  • B) Inhibition of 5-lipoxygenase
  • C) Antagonism of cysteinyl leukotriene CysLT1 receptors
  • D) Mast cell stabilization
Answer: C - Antagonism of cysteinyl leukotriene CysLT1 receptors Rationale: Montelukast is a selective CysLT1 receptor antagonist. Leukotrienes (LTC4, LTD4, LTE4) cause bronchoconstriction, mucus secretion, and airway edema. Blocking CysLT1 reduces these effects.
Q4. Theophylline's primary mechanism of action as a bronchodilator is:
  • A) Beta-2 receptor agonism
  • B) Phosphodiesterase inhibition increasing intracellular cAMP
  • C) Muscarinic receptor antagonism
  • D) Leukotriene receptor antagonism
Answer: B - Phosphodiesterase inhibition increasing intracellular cAMP Rationale: Theophylline inhibits phosphodiesterase, preventing the breakdown of cAMP, which relaxes bronchial smooth muscle. It also has anti-inflammatory properties and stimulates the respiratory center. (Katzung's Pharmacology; Fishman's Pulmonary Diseases)
Q5. A 22-year-old asthmatic presents with acute severe exacerbation. His peak flow is 40% predicted. The FIRST drug to administer is:
  • A) IV methylprednisolone
  • B) Inhaled ipratropium bromide
  • C) Nebulized albuterol (salbutamol)
  • D) IV magnesium sulfate
Answer: C - Nebulized albuterol (salbutamol) Rationale: Short-acting beta-2 agonists (SABA) are the first-line bronchodilators in acute asthma exacerbation. Albuterol causes rapid bronchodilation within minutes. Systemic corticosteroids reduce inflammation but have delayed onset.
Q6. Which drug combination is CONTRAINDICATED in asthma management?
  • A) ICS + LABA
  • B) LABA monotherapy without ICS in asthma
  • C) Montelukast + ICS
  • D) Ipratropium + albuterol
Answer: B - LABA monotherapy without ICS in asthma Rationale: LABAs should NEVER be used as monotherapy in asthma due to increased risk of asthma-related deaths (black box warning, FDA). LABAs must always be used with an ICS in asthma. (Katzung's Pharmacology)
Q7. The therapeutic serum level of theophylline for asthma management is:
  • A) 2-5 mcg/mL
  • B) 5-10 mcg/mL
  • C) 10-20 mcg/mL
  • D) 20-30 mcg/mL
Answer: C - 10-20 mcg/mL Rationale: The therapeutic window for theophylline is 10-20 mcg/mL. Levels above 20 mcg/mL cause toxicity (nausea, seizures, arrhythmias). This narrow therapeutic index requires TDM. (Fishman's Pulmonary Diseases)
Q8. Omalizumab is indicated for which type of asthma?
  • A) Exercise-induced asthma
  • B) Moderate-to-severe persistent allergic (IgE-mediated) asthma
  • C) Non-allergic asthma with normal IgE
  • D) Aspirin-exacerbated asthma
Answer: B - Moderate-to-severe persistent allergic (IgE-mediated) asthma Rationale: Omalizumab is an anti-IgE monoclonal antibody that reduces free serum IgE, preventing mast cell degranulation. It is indicated for patients with elevated IgE and confirmed allergen sensitization. (Katzung's Pharmacology)
Q9. A patient reports worsening of asthma symptoms after starting a new medication for hypertension. Which drug is most likely responsible?
  • A) Amlodipine
  • B) Propranolol
  • C) Lisinopril
  • D) Losartan
Answer: B - Propranolol Rationale: Non-selective beta-blockers like propranolol block beta-2 receptors in the airways, causing bronchoconstriction. They are contraindicated in asthma. Lisinopril causes dry cough (not bronchospasm per se) but ACE inhibitors should be used cautiously.
Q10. Salmeterol differs from albuterol in that salmeterol:
  • A) Acts faster (onset 1-3 minutes)
  • B) Is short-acting (4-6 hours duration)
  • C) Has a 12-hour duration and long lipophilic tail anchoring it in the cell membrane
  • D) Is selective for beta-1 receptors
Answer: C - Has a 12-hour duration and long lipophilic tail anchoring it in the cell membrane Rationale: Salmeterol has a long lipophilic side chain that anchors it to the cell membrane near the beta-2 receptor, providing 12-hour duration of action. Albuterol has rapid onset (1-5 min) and short duration (4-6 hours). (Goodman & Gilman's Pharmacology)
Q11. Which inhaler device requires the least inspiratory flow rate coordination and is preferred in patients with poor inhaler technique?
  • A) Dry powder inhaler (DPI)
  • B) Metered-dose inhaler (MDI) without spacer
  • C) Soft mist inhaler
  • D) Nebulizer
Answer: D - Nebulizer Rationale: Nebulizers convert liquid medication to fine mist and do not require inspiratory flow coordination or breath-holding, making them ideal for acute exacerbations, young children, and elderly patients with poor technique.
Q12. Aspirin-exacerbated respiratory disease (AERD) is best treated with:
  • A) High-dose aspirin desensitization followed by chronic aspirin therapy
  • B) Leukotriene receptor antagonists (e.g., montelukast)
  • C) Antihistamines
  • D) Inhaled corticosteroids only
Answer: B - Leukotriene receptor antagonists (e.g., montelukast) Rationale: NSAID/aspirin ingestion shunts arachidonic acid toward the leukotriene pathway, causing bronchoconstriction. Leukotriene antagonists are particularly effective in AERD. Aspirin desensitization is used in select patients requiring aspirin.
Q13. Exercise-induced bronchoconstriction is best prevented by administering which drug 15 minutes before exercise?
  • A) Formoterol
  • B) Albuterol (SABA)
  • C) Fluticasone
  • D) Montelukast
Answer: B - Albuterol (SABA) Rationale: Inhaled SABAs (albuterol) are the first-line pretreatment for exercise-induced bronchoconstriction. They should be inhaled 15-30 minutes before exercise. LABAs (formoterol) are used for persistent exercise-induced bronchospasm unresponsive to SABAs.
Q14. Which cytokine is the primary mediator of eosinophilic airway inflammation in asthma and the target of mepolizumab?
  • A) IL-4
  • B) IL-5
  • C) IL-13
  • D) IFN-gamma
Answer: B - IL-5 Rationale: IL-5 is responsible for eosinophil differentiation, maturation, and survival. Mepolizumab is an anti-IL-5 monoclonal antibody that reduces blood and tissue eosinophils, indicated for severe eosinophilic asthma.
Q15. A patient's spirometry shows FEV1/FVC of 0.65 (normal >0.70) with FVC within normal limits. This pattern is consistent with:
  • A) Restrictive lung disease
  • B) Obstructive lung disease
  • C) Mixed pattern
  • D) Normal spirometry
Answer: B - Obstructive lung disease Rationale: A reduced FEV1/FVC ratio (<0.70) with normal or increased FVC indicates airflow obstruction (e.g., asthma, COPD). Restrictive disease shows reduced FVC with preserved or elevated FEV1/FVC ratio.
Q16. Which drug used in asthma acts by stabilizing mast cell membranes and preventing degranulation?
  • A) Ketotifen
  • B) Cromolyn sodium
  • C) Nedocromil
  • D) Both B and C
Answer: D - Both B and C Rationale: Cromolyn sodium and nedocromil are mast cell stabilizers that inhibit degranulation and mediator release. They are used as preventive therapy, particularly in mild persistent asthma and exercise-induced bronchospasm, though less commonly used now.
Q17. The Global Initiative for Asthma (GINA) classifies asthma severity. A patient with daily symptoms, nighttime awakening >1/week, and FEV1 60-80% predicted is classified as:
  • A) Mild intermittent
  • B) Mild persistent
  • C) Moderate persistent
  • D) Severe persistent
Answer: C - Moderate persistent Rationale: GINA moderate persistent asthma: daily symptoms, nighttime symptoms >1x/week (not nightly), FEV1 60-80% predicted, FEV1/FVC reduced >5%. Step 3 or 4 therapy is required.
Q18. What is the preferred rescue inhaler for acute asthma?
  • A) Salmeterol
  • B) Albuterol (salbutamol)
  • C) Ipratropium
  • D) Tiotropium
Answer: B - Albuterol (salbutamol) Rationale: Albuterol is the preferred SABA for acute asthma rescue due to rapid onset (1-5 minutes), short duration, and high beta-2 selectivity. Tiotropium and salmeterol are long-acting and not appropriate for acute relief.
Q19. Which of the following describes the mechanism of ICS (inhaled corticosteroids) in asthma?
  • A) Direct bronchodilation via beta-2 receptors
  • B) Reduction of airway inflammation via glucocorticoid receptor-mediated gene regulation
  • C) Mast cell membrane stabilization
  • D) Leukotriene synthesis inhibition
Answer: B - Reduction of airway inflammation via glucocorticoid receptor-mediated gene regulation Rationale: ICS bind intracellular glucocorticoid receptors, translocate to the nucleus, and modulate gene expression - downregulating pro-inflammatory cytokines (IL-4, IL-5, IL-13) and upregulating anti-inflammatory proteins. They reduce airway hyperresponsiveness over weeks.
Q20. A child with mild persistent asthma is prescribed montelukast. Which adverse effect should be specifically monitored?
  • A) Candida infection
  • B) Adrenal suppression
  • C) Neuropsychiatric events (depression, suicidal ideation)
  • D) QT prolongation
Answer: C - Neuropsychiatric events (depression, suicidal ideation) Rationale: The FDA issued a black box warning for montelukast in 2020 regarding serious neuropsychiatric adverse events including agitation, depression, sleep disturbances, and suicidal ideation. Benefits must be weighed against risks in mild asthma.
Q21. Dupilumab is a biologic approved for severe asthma. It targets:
  • A) IgE
  • B) IL-5
  • C) IL-4 receptor alpha (blocking both IL-4 and IL-13 signaling)
  • D) TSLP
Answer: C - IL-4 receptor alpha (blocking both IL-4 and IL-13 signaling) Rationale: Dupilumab blocks the IL-4 receptor alpha subunit, which is shared by both IL-4 and IL-13 receptors. It reduces type 2 airway inflammation and is approved for moderate-to-severe eosinophilic asthma and other atopic conditions.
Q22. A patient presents with acute severe asthma not responding to repeated nebulized albuterol and IV corticosteroids. Which IV agent should be considered next?
  • A) IV theophylline
  • B) IV magnesium sulfate
  • C) IV epinephrine
  • D) IV ketamine
Answer: B - IV magnesium sulfate Rationale: IV magnesium sulfate (single dose 2g over 20 minutes) is recommended for acute severe asthma unresponsive to initial bronchodilator therapy. It relaxes bronchial smooth muscle by blocking calcium channels. (Emergency guidelines)
Q23. Which of the following about albuterol pharmacokinetics is CORRECT?
  • A) It is a prodrug requiring hepatic activation
  • B) Oral bioavailability is >90%
  • C) Inhaled route delivers 10-20% of the dose to the lungs
  • D) It has a half-life of 12 hours
Answer: C - Inhaled route delivers 10-20% of the dose to the lungs Rationale: With a standard MDI without spacer, approximately 10-20% of the dose reaches the lower airways; the remainder is deposited in the oropharynx and swallowed. A spacer increases lung deposition.
Q24. Zileuton is used in asthma. Its mechanism of action is:
  • A) CysLT1 receptor antagonism
  • B) 5-lipoxygenase inhibition, blocking all leukotriene synthesis
  • C) Phosphodiesterase inhibition
  • D) IL-5 antagonism
Answer: B - 5-lipoxygenase inhibition, blocking all leukotriene synthesis Rationale: Zileuton inhibits 5-lipoxygenase, the enzyme that converts arachidonic acid to leukotriene A4. This blocks ALL leukotriene synthesis. It requires liver function monitoring due to hepatotoxicity risk. Montelukast/zafirlukast block the CysLT1 receptor.
Q25. Which adverse effect is associated with long-term use of high-dose inhaled corticosteroids?
  • A) Hyperkalemia
  • B) Oropharyngeal candidiasis and hoarseness
  • C) Hypertension
  • D) Peptic ulcer disease
Answer: B - Oropharyngeal candidiasis and hoarseness Rationale: ICS deposit in the oropharynx, causing local immunosuppression leading to Candida infection (thrush) and dysphonia (hoarseness). Patients should rinse their mouth after each use. Systemic effects occur with higher doses. (Katzung's Pharmacology)

SECTION 2: COPD (Questions 26-50)

Q26. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) defines COPD as:
  • A) FEV1/FVC > 0.70 post-bronchodilator
  • B) Post-bronchodilator FEV1/FVC < 0.70 with respiratory symptoms
  • C) FVC < 80% predicted
  • D) Any patient with chronic cough and sputum production
Answer: B - Post-bronchodilator FEV1/FVC < 0.70 with respiratory symptoms Rationale: COPD is confirmed by post-bronchodilator spirometry showing FEV1/FVC < 0.70, combined with respiratory symptoms (dyspnea, cough, sputum) and risk factor exposure (primarily cigarette smoking). (GOLD Guidelines; Costanzo Physiology)
Q27. The most common cause of COPD worldwide is:
  • A) Alpha-1 antitrypsin deficiency
  • B) Occupational dust exposure
  • C) Cigarette smoking
  • D) Air pollution
Answer: C - Cigarette smoking Rationale: Cigarette smoking is responsible for approximately 85-90% of COPD cases. It causes oxidative stress, airway inflammation, and protease-antiprotease imbalance leading to emphysema and chronic bronchitis. (Robbins Pathology; Fishman's Pulmonary)
Q28. Tiotropium's mechanism of action in COPD is:
  • A) Long-acting beta-2 receptor agonism
  • B) Long-acting muscarinic receptor antagonism (LAMA) - blocks M1 and M3 receptors
  • C) Phosphodiesterase-4 inhibition
  • D) Leukotriene receptor antagonism
Answer: B - Long-acting muscarinic receptor antagonism (LAMA) - blocks M1 and M3 receptors Rationale: Tiotropium is a LAMA that preferentially dissociates from M2 receptors rapidly but binds M1 and M3 receptors for 24 hours, reducing bronchoconstriction and mucus secretion. Once-daily dosing. (Katzung's Pharmacology)
Q29. Which drug is preferred as the initial maintenance therapy for a COPD patient with few symptoms (GOLD A)?
  • A) Inhaled corticosteroid alone
  • B) Short-acting bronchodilator (SABA or SAMA) as needed
  • C) LABA + LAMA combination
  • D) Roflumilast
Answer: B - Short-acting bronchodilator (SABA or SAMA) as needed Rationale: GOLD Group A patients have few symptoms (mMRC 0-1, CAT <10) and low exacerbation risk. GOLD guidelines recommend a short-acting bronchodilator (albuterol or ipratropium) as needed. Long-acting agents are for Groups B, C, D. (GOLD 2023)
Q30. Roflumilast is used in severe COPD. Its mechanism is:
  • A) Beta-2 agonism
  • B) Selective phosphodiesterase-4 (PDE-4) inhibition, reducing airway inflammation
  • C) Muscarinic receptor antagonism
  • D) Mucolytic action
Answer: B - Selective phosphodiesterase-4 (PDE-4) inhibition, reducing airway inflammation Rationale: Roflumilast inhibits PDE-4, preventing cAMP breakdown in inflammatory cells (neutrophils, eosinophils, macrophages). It is an oral anti-inflammatory agent indicated as add-on therapy in severe COPD with chronic bronchitis and frequent exacerbations. (Katzung's Pharmacology)
Q31. Alpha-1 antitrypsin (AAT) deficiency causes COPD predominantly involving which part of the lung?
  • A) Upper lobes (apical)
  • B) Lower lobes (basal)
  • C) Middle lobe
  • D) Perihilar region
Answer: B - Lower lobes (basal) Rationale: AAT deficiency causes panacinar emphysema predominantly affecting the lower lobes because AAT deficiency allows neutrophil elastase to destroy alveolar walls. Smoking-related emphysema predominantly affects upper lobes (centrilobular). (Robbins Pathology)
Q32. The pathological type of emphysema most associated with cigarette smoking is:
  • A) Panacinar emphysema
  • B) Centrilobular (centriacinar) emphysema
  • C) Paraseptal emphysema
  • D) Irregular emphysema
Answer: B - Centrilobular (centriacinar) emphysema Rationale: Centrilobular emphysema affects the central portion of the acinus (respiratory bronchioles), predominantly in upper lobes, and is strongly associated with cigarette smoking. Panacinar emphysema is associated with AAT deficiency. (Robbins Pathology)
Q33. A COPD patient presents with acute exacerbation with increased dyspnea and purulent sputum. Which is the MOST COMMON bacterial cause?
  • A) Pseudomonas aeruginosa
  • B) Haemophilus influenzae
  • C) Staphylococcus aureus
  • D) Klebsiella pneumoniae
Answer: B - Haemophilus influenzae Rationale: H. influenzae (non-typeable) is the most common bacterial pathogen in COPD exacerbations, followed by Streptococcus pneumoniae and Moraxella catarrhalis. Pseudomonas is seen in patients with advanced COPD (FEV1 <35%).
Q34. The "pink puffer" phenotype of COPD is associated with:
  • A) Chronic bronchitis (Blue bloater)
  • B) Emphysema with hyperinflation, pursed-lip breathing, barrel chest
  • C) Cor pulmonale
  • D) Polycythemia
Answer: B - Emphysema with hyperinflation, pursed-lip breathing, barrel chest Rationale: "Pink puffers" (emphysema type) maintain normal PaO2 through increased work of breathing (pursed lips, accessory muscles). "Blue bloaters" (chronic bronchitis type) hypoventilate, develop hypoxia, cyanosis, and cor pulmonale. (Robbins Pathology; Fishman's)
Q35. Which finding on pulmonary function testing distinguishes COPD from asthma most definitively?
  • A) Reduced FEV1
  • B) Reduced FEV1/FVC ratio
  • C) Irreversibility of obstruction after bronchodilator administration
  • D) Reduced DLCO
Answer: C - Irreversibility of obstruction after bronchodilator administration Rationale: Asthma shows significant reversibility (>12% and 200mL increase in FEV1 after bronchodilator). COPD typically shows minimal or no reversibility. However, some overlap exists. Post-bronchodilator FEV1/FVC < 0.70 is the GOLD diagnostic criterion for COPD.
Q36. Long-term oxygen therapy (LTOT) in COPD is indicated when:
  • A) PaO2 ≤ 55 mmHg at rest or SpO2 ≤ 88%
  • B) PaO2 ≤ 65 mmHg at rest
  • C) FEV1 < 50% predicted
  • D) Any patient with COPD and dyspnea
Answer: A - PaO2 ≤ 55 mmHg at rest or SpO2 ≤ 88% Rationale: LTOT (≥15 hours/day) is the only pharmacological intervention shown to reduce mortality in COPD patients with chronic hypoxemia. Criteria: PaO2 ≤55 mmHg (or SpO2 ≤88%), or PaO2 56-60 mmHg with cor pulmonale/polycythemia. (GOLD Guidelines)
Q37. A patient with COPD is started on ipratropium bromide. The mechanism of this SAMA is:
  • A) Beta-2 agonism causing bronchodilation
  • B) Competitive antagonism of muscarinic (M3) receptors reducing bronchoconstriction and mucus secretion
  • C) Phosphodiesterase inhibition
  • D) Mast cell stabilization
Answer: B - Competitive antagonism of muscarinic (M3) receptors reducing bronchoconstriction and mucus secretion Rationale: Ipratropium is a short-acting muscarinic antagonist (SAMA) that blocks M3 receptors in bronchial smooth muscle and glands, reducing bronchoconstriction and mucus secretion. It is preferred over SABAs as maintenance in stable COPD by some guidelines. (Katzung's Pharmacology)
Q38. Which scoring system is used to assess COPD symptom burden in the GOLD classification?
  • A) APACHE II score
  • B) CURB-65
  • C) CAT (COPD Assessment Test) score
  • D) MRC dyspnea scale only
Answer: C - CAT (COPD Assessment Test) score Rationale: The CAT score (0-40) and mMRC dyspnea scale assess symptom burden in COPD. CAT ≥10 or mMRC ≥2 classifies patients as "more symptomatic" (Groups B or D). Combined with exacerbation risk, this guides pharmacotherapy. (GOLD 2023)
Q39. N-acetylcysteine (NAC) in COPD works as:
  • A) Bronchodilator
  • B) Mucolytic agent breaking disulfide bonds in mucus + antioxidant
  • C) Anti-inflammatory via PDE-4 inhibition
  • D) Antibiotic
Answer: B - Mucolytic agent breaking disulfide bonds in mucus + antioxidant Rationale: NAC breaks disulfide bonds in mucus glycoproteins, reducing viscosity. It also replenishes glutathione, providing antioxidant protection. Evidence for reducing exacerbations is modest. (Fishman's Pulmonary Diseases)
Q40. Which COPD medication has a black box warning for suicidal ideation and behavior?
  • A) Tiotropium
  • B) Roflumilast
  • C) Theophylline
  • D) Salmeterol
Answer: B - Roflumilast Rationale: Roflumilast (PDE-4 inhibitor) carries an FDA warning regarding psychiatric adverse effects including suicidal ideation. It is also associated with significant weight loss (average 2 kg) and GI side effects (diarrhea, nausea). (Katzung's Pharmacology)
Q41. The chronic bronchitis phenotype of COPD is defined clinically as:
  • A) FEV1/FVC < 0.70 for >6 months
  • B) Productive cough for at least 3 months per year for 2 consecutive years
  • C) DLCO < 70% predicted
  • D) Sputum production daily for 1 month
Answer: B - Productive cough for at least 3 months per year for 2 consecutive years Rationale: Chronic bronchitis is defined clinically (not spirometrically) as productive cough on most days for ≥3 months/year for ≥2 consecutive years, with other causes excluded. It is characterized by mucus gland hypertrophy (Reid index >0.4). (Robbins Pathology)
Q42. In COPD exacerbation management, systemic corticosteroids should be given for:
  • A) 3-5 days
  • B) 5-7 days
  • C) 10-14 days
  • D) 21 days
Answer: B - 5-7 days Rationale: GOLD guidelines and multiple RCTs support 5-7 days of systemic corticosteroids (prednisolone 40mg/day) for COPD exacerbations requiring hospitalization. Shorter courses (5 days) are as effective as longer courses (10-14 days) with fewer side effects.
Q43. Which vaccine is recommended for ALL patients with COPD?
  • A) Pneumococcal vaccine only
  • B) Influenza vaccine annually
  • C) Both influenza and pneumococcal vaccines
  • D) Hepatitis B vaccine
Answer: C - Both influenza and pneumococcal vaccines Rationale: GOLD guidelines recommend annual influenza vaccination (reduces exacerbations and mortality) and pneumococcal vaccination (PCV13 and PPSV23) for all COPD patients. These are key non-pharmacological interventions.
Q44. Aclidinium bromide is a LAMA approved for COPD maintenance. Its dosing frequency compared to tiotropium is:
  • A) Once daily (same as tiotropium)
  • B) Twice daily
  • C) Three times daily
  • D) Four times daily
Answer: B - Twice daily Rationale: Aclidinium is dosed twice daily (unlike tiotropium which is once daily). This is due to its faster dissociation from M3 receptors. Aclidinium may also cause less dry mouth than tiotropium.
Q45. Indacaterol is a LABA used in COPD. How often is it dosed?
  • A) Every 4-6 hours
  • B) Twice daily (same as formoterol and salmeterol)
  • C) Once daily
  • D) Every 8 hours
Answer: C - Once daily Rationale: Indacaterol is a once-daily LABA with a 24-hour duration. It provides faster onset than salmeterol and is approved for COPD maintenance therapy (not asthma). (Katzung's Pharmacology)
Q46. Which fixed-dose combination inhaler is the FIRST LABA/LAMA approved for COPD?
  • A) Umeclidinium/vilanterol (Anoro Ellipta)
  • B) Tiotropium/olodaterol (Stiolto Respimat)
  • C) Indacaterol/glycopyrronium (Ultibro Breezhaler)
  • D) Aclidinium/formoterol (Duaklir)
Answer: A - Umeclidinium/vilanterol (Anoro Ellipta) Rationale: Umeclidinium/vilanterol was the first LAMA/LABA combination approved by FDA for COPD maintenance, dosed once daily via the Ellipta dry powder inhaler.
Q47. In COPD, pulmonary rehabilitation is MOST effective for:
  • A) Improving FEV1
  • B) Reducing dyspnea and improving exercise capacity and quality of life
  • C) Eliminating the need for bronchodilators
  • D) Curing airway obstruction
Answer: B - Reducing dyspnea and improving exercise capacity and quality of life Rationale: Pulmonary rehabilitation does not improve FEV1 but significantly reduces dyspnea, increases exercise tolerance, and improves health-related quality of life. It also reduces hospitalizations and exacerbations. (GOLD Guidelines)
Q48. The "barrel chest" seen in COPD emphysema is due to:
  • A) Pleural effusion
  • B) Air trapping causing lung hyperinflation and increased AP chest diameter
  • C) Cardiomegaly
  • D) Fibrosis of the chest wall
Answer: B - Air trapping causing lung hyperinflation and increased AP chest diameter Rationale: Air trapping in emphysema causes lung hyperinflation. The diaphragm flattens, the chest expands permanently, and the AP/lateral diameter ratio increases to approximately 1:1 (normal 1:2), giving the barrel chest appearance. (Costanzo Physiology)
Q49. The mechanism of hypoxemia in COPD is primarily:
  • A) Diffusion impairment (thickened alveolar membrane)
  • B) Ventilation-perfusion (V/Q) mismatch
  • C) Shunting
  • D) Hypoventilation alone
Answer: B - Ventilation-perfusion (V/Q) mismatch Rationale: COPD causes uneven airflow distribution. Some lung regions are poorly ventilated but still perfused (low V/Q), leading to hypoxemia. This is the dominant mechanism. In late-stage COPD, global hypoventilation also contributes. (Costanzo Physiology; Fishman's)
Q50. Smoking cessation in COPD patients has which effect?
  • A) Reverses airway obstruction to normal
  • B) Slows the rate of FEV1 decline toward that of non-smokers
  • C) Has no effect once COPD is established
  • D) Causes initial worsening of lung function
Answer: B - Slows the rate of FEV1 decline toward that of non-smokers Rationale: Smoking cessation is the single most effective intervention in COPD. It slows the accelerated annual FEV1 decline (60-80 mL/year in smokers) toward the normal aging rate (20-30 mL/year), but does not restore lost function. (GOLD; Fishman's)

SECTION 3: PNEUMONIA (Questions 51-65)

Q51. The most common cause of community-acquired pneumonia (CAP) in adults is:
  • A) Haemophilus influenzae
  • B) Mycoplasma pneumoniae
  • C) Streptococcus pneumoniae
  • D) Legionella pneumophila
Answer: C - Streptococcus pneumoniae Rationale: S. pneumoniae is the most common identified bacterial cause of CAP in all age groups and across all severity levels. It causes classic "lobar" pneumonia with rust-colored sputum and lobar consolidation. (Goldman-Cecil Medicine)
Q52. The CURB-65 score assesses CAP severity. The "B" component stands for:
  • A) Bacteremia
  • B) Blood urea nitrogen > 19 mg/dL (>7 mmol/L)
  • C) Bilateral infiltrates
  • D) Bronchopneumonia
Answer: B - Blood urea nitrogen > 19 mg/dL (>7 mmol/L) Rationale: CURB-65 criteria: Confusion, Urea >7mmol/L (BUN >19mg/dL), Respiratory rate ≥30/min, Blood pressure (systolic <90 or diastolic ≤60 mmHg), age ≥65. Score 0-1 = outpatient, 2 = consider hospitalization, ≥3 = severe/ICU.
Q53. Atypical pneumonia caused by Mycoplasma pneumoniae is best treated with:
  • A) Beta-lactam antibiotics (penicillin, amoxicillin)
  • B) Macrolides (azithromycin) or tetracyclines (doxycycline)
  • C) Aminoglycosides
  • D) Vancomycin
Answer: B - Macrolides (azithromycin) or tetracyclines (doxycycline) Rationale: Mycoplasma lacks a cell wall, so beta-lactams are ineffective. Macrolides, tetracyclines, and fluoroquinolones target protein synthesis or DNA replication and are effective. Azithromycin is preferred. (Fishman's Pulmonary)
Q54. Legionella pneumophila pneumonia (Legionnaires' disease) is associated with which epidemiological clue?
  • A) Contact with birds (parrots, pigeons)
  • B) Exposure to contaminated water sources (cooling towers, hot tubs, hospital water systems)
  • C) Contact with soil during construction
  • D) Travel to Southwest USA
Answer: B - Exposure to contaminated water sources (cooling towers, hot tubs, hospital water systems) Rationale: Legionella thrives in warm water. Outbreaks occur via aerosolization from cooling towers, air conditioning systems, and decorative fountains. It does NOT spread person-to-person. Treatment: fluoroquinolones or macrolides. (Goldman-Cecil Medicine)
Q55. The drug of choice for treating severe CAP in hospitalized patients (non-ICU) is:
  • A) Azithromycin monotherapy
  • B) Beta-lactam (ampicillin-sulbactam or ceftriaxone) + macrolide (azithromycin)
  • C) Vancomycin alone
  • D) Amoxicillin alone
Answer: B - Beta-lactam (ampicillin-sulbactam or ceftriaxone) + macrolide (azithromycin) Rationale: IDSA/ATS guidelines for hospitalized non-ICU CAP recommend beta-lactam + macrolide combination, or monotherapy with a respiratory fluoroquinolone (levofloxacin, moxifloxacin). Combination therapy covers both typical and atypical organisms.
Q56. Hospital-acquired pneumonia (HAP) occurring after 48 hours of hospitalization should be treated empirically with coverage for:
  • A) S. pneumoniae only
  • B) Gram-negative bacilli (including Pseudomonas) and MRSA
  • C) Atypical organisms
  • D) Anaerobes only
Answer: B - Gram-negative bacilli (including Pseudomonas) and MRSA Rationale: HAP pathogens include gram-negative bacilli (Pseudomonas, Klebsiella, Acinetobacter, E. coli) and MRSA. Empiric therapy includes anti-Pseudomonal beta-lactam + anti-MRSA agent (vancomycin or linezolid) in high-risk patients. (Goldman-Cecil Medicine)
Q57. Pneumocystis jirovecii pneumonia (PCP) is most likely to occur when CD4 count falls below:
  • A) 500 cells/mm³
  • B) 350 cells/mm³
  • C) 200 cells/mm³
  • D) 100 cells/mm³
Answer: C - 200 cells/mm³ Rationale: PCP occurs when CD4 count <200 cells/mm³ in HIV-infected patients. Primary prophylaxis with TMP-SMX is initiated when CD4 <200. Classic presentation: progressive dyspnea, dry cough, bilateral ground-glass infiltrates, elevated LDH. (Goldman-Cecil Medicine)
Q58. The drug of choice for PCP (Pneumocystis jirovecii pneumonia) is:
  • A) Fluconazole
  • B) Trimethoprim-sulfamethoxazole (TMP-SMX)
  • C) Amphotericin B
  • D) Voriconazole
Answer: B - Trimethoprim-sulfamethoxazole (TMP-SMX) Rationale: TMP-SMX (Bactrim) is both the treatment of choice and prophylaxis agent for PCP. Treatment dose: TMP 15-20 mg/kg/day + SMX IV/PO for 21 days. Adjunctive prednisone is added for moderate-to-severe PCP (PaO2 <70 mmHg). (Goldman-Cecil Medicine)
Q59. Which chest X-ray finding is MOST characteristic of primary tuberculosis?
  • A) Bilateral hilar lymphadenopathy (Ghon complex + Ranke complex)
  • B) Cavitation in upper lobes
  • C) Bilateral lower lobe infiltrates
  • D) Pleural effusion only
Answer: A - Bilateral hilar lymphadenopathy (Ghon complex + Ranke complex) Rationale: Primary TB forms a Ghon complex (peripheral parenchymal focus + draining lymph nodes). This can calcify to form the Ranke complex. Reactivation TB causes upper lobe cavitary disease. (Robbins Pathology)
Q60. Aspiration pneumonia most commonly involves which lung segment?
  • A) Left upper lobe anterior segment
  • B) Right lower lobe posterior segment (superior segment when supine)
  • C) Right middle lobe
  • D) Left lower lobe
Answer: B - Right lower lobe posterior segment (superior segment when supine) Rationale: Aspiration occurs most easily into the right bronchus (shorter, wider, more vertical). When supine: superior segment of RLL. When upright: basal segments of RLL. Anaerobes are common pathogens, and clindamycin or amoxicillin-clavulanate is used.
Q61. A patient with viral influenza pneumonia develops sudden worsening with rigors, productive sputum, and new lobar consolidation. Which secondary bacterial pathogen is most likely?
  • A) Pseudomonas aeruginosa
  • B) Staphylococcus aureus (including MRSA)
  • C) Legionella pneumophila
  • D) Mycoplasma pneumoniae
Answer: B - Staphylococcus aureus (including MRSA) Rationale: Post-influenza bacterial pneumonia most commonly involves S. aureus, S. pneumoniae, and H. influenzae. MRSA causes particularly severe necrotizing pneumonia with cavitation. Influenza damages mucociliary clearance and innate immunity.
Q62. Which diagnostic test has the highest sensitivity for detecting Legionella pneumonia rapidly?
  • A) Sputum Gram stain
  • B) Blood cultures
  • C) Urinary antigen test (UAT)
  • D) Serology (IFA)
Answer: C - Urinary antigen test (UAT) Rationale: Legionella urinary antigen test detects L. pneumophila serogroup 1 (responsible for ~80-90% of cases) with sensitivity 70-80% and specificity >99%. Results are rapid (hours). Serogroup 1 is the most common clinical isolate.
Q63. For outpatient treatment of CAP in a healthy patient with no comorbidities and no recent antibiotic use, the recommended therapy is:
  • A) Amoxicillin-clavulanate
  • B) Azithromycin or doxycycline (monotherapy)
  • C) Ciprofloxacin
  • D) Levofloxacin
Answer: B - Azithromycin or doxycycline (monotherapy) Rationale: IDSA/ATS guidelines recommend macrolide (azithromycin) or doxycycline for outpatient CAP in otherwise healthy adults with no recent antibiotic use. Amoxicillin is an alternative. Respiratory fluoroquinolones (levofloxacin) are reserved for patients with comorbidities.
Q64. Which immunological test is used to diagnose tuberculosis in immunocompetent patients and is not affected by BCG vaccination?
  • A) Tuberculin skin test (TST/Mantoux)
  • B) Interferon-gamma release assay (IGRA) such as QuantiFERON-TB Gold
  • C) Acid-fast sputum smear
  • D) Chest X-ray
Answer: B - Interferon-gamma release assay (IGRA) such as QuantiFERON-TB Gold Rationale: IGRAs measure interferon-gamma production by sensitized T-cells in response to TB-specific antigens (ESAT-6, CFP-10) not present in BCG or most non-tuberculosis mycobacteria. Unlike TST, IGRAs are not affected by prior BCG vaccination.
Q65. The standard 4-drug regimen for drug-susceptible pulmonary tuberculosis consists of:
  • A) INH + Rifampin + Pyrazinamide + Ethambutol for 2 months, then INH + Rifampin for 4 months
  • B) INH + Rifampin for 9 months only
  • C) INH monotherapy for 12 months
  • D) INH + Ethambutol + Streptomycin for 6 months
Answer: A - INH + Rifampin + Pyrazinamide + Ethambutol for 2 months, then INH + Rifampin for 4 months Rationale: The 6-month RIPE regimen: Initial phase (2 months) - Rifampin + Isoniazid + Pyrazinamide + Ethambutol; Continuation phase (4 months) - Rifampin + Isoniazid. This is the WHO/CDC standard for drug-susceptible TB. (Katzung's Pharmacology; Goldman-Cecil Medicine)

SECTION 4: TUBERCULOSIS PHARMACOLOGY (Questions 66-75)

Q66. Isoniazid (INH) causes peripheral neuropathy due to interference with:
  • A) Folate synthesis
  • B) Pyridoxine (Vitamin B6) metabolism
  • C) Riboflavin (Vitamin B2)
  • D) Cobalamin (Vitamin B12)
Answer: B - Pyridoxine (Vitamin B6) metabolism Rationale: INH competitively inhibits pyridoxine metabolism, causing peripheral neuropathy. Pyridoxine supplementation (25-50 mg/day) is given prophylactically to high-risk patients (malnourished, pregnant, diabetic, HIV-infected). (Katzung's Pharmacology)
Q67. The primary adverse effect of Ethambutol requiring regular monitoring is:
  • A) Hepatotoxicity
  • B) Optic neuritis (decreased visual acuity and red-green color discrimination)
  • C) Hyperuricemia
  • D) Peripheral neuropathy
Answer: B - Optic neuritis (decreased visual acuity and red-green color discrimination) Rationale: Ethambutol inhibits arabinosyl transferase (mycobacterial cell wall synthesis) and causes dose-dependent optic neuritis, presenting as decreased visual acuity, blurred vision, and red-green color blindness. Monthly visual testing is required. (Katzung's Pharmacology)
Q68. Rifampin is a potent enzyme inducer of:
  • A) CYP2D6
  • B) CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein
  • C) CYP1A2 only
  • D) MAO enzymes
Answer: B - CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein Rationale: Rifampin is one of the most potent inducers of multiple CYP450 enzymes and P-glycoprotein. It significantly reduces levels of many drugs including warfarin, HIV antiretrovirals, oral contraceptives, and azole antifungals. Drug interactions must be closely monitored. (Katzung's Pharmacology)
Q69. Pyrazinamide is primarily used in the initial 2-month phase of TB treatment. Its most common dose-limiting adverse effect is:
  • A) Optic neuritis
  • B) Hepatotoxicity and hyperuricemia (gout)
  • C) Peripheral neuropathy
  • D) Orange discoloration of secretions
Answer: B - Hepatotoxicity and hyperuricemia (gout) Rationale: Pyrazinamide inhibits renal urate secretion, causing hyperuricemia (and gout). It is also hepatotoxic. Baseline LFTs and uric acid monitoring are required. Drug is bactericidal in the acidic environment of macrophages. (Katzung's Pharmacology)
Q70. Multidrug-resistant TB (MDR-TB) is defined as resistance to:
  • A) Any two TB drugs
  • B) Isoniazid and Rifampin (the two most effective first-line agents)
  • C) All first-line agents
  • D) Ethambutol and Streptomycin
Answer: B - Isoniazid and Rifampin (the two most effective first-line agents) Rationale: MDR-TB = resistance to at minimum INH and Rifampin. XDR-TB = MDR-TB + resistance to fluoroquinolones + second-line injectable agents. Treatment requires second-line agents (bedaquiline, delamanid, linezolid) for 18-24+ months.
Q71. Latent tuberculosis infection (LTBI) treatment in HIV-positive patients uses which preferred regimen?
  • A) INH monotherapy for 9 months (9H)
  • B) INH + Rifapentine once weekly for 3 months (3HP)
  • C) INH + Rifampin for 3 months
  • D) Rifampin monotherapy for 4 months
Answer: B - INH + Rifapentine once weekly for 3 months (3HP) Rationale: The 3HP regimen (12 weekly doses of INH + Rifapentine under DOT) is now preferred for LTBI by CDC/WHO, including HIV-positive patients not on antiretrovirals. It has better completion rates than 9-month INH. Drug interactions with ART must be considered. (Lippincott Pharmacology; Goldman-Cecil)
Q72. Which antituberculosis drug can cause an orange discoloration of urine, tears, and sweat?
  • A) Isoniazid
  • B) Ethambutol
  • C) Pyrazinamide
  • D) Rifampin
Answer: D - Rifampin Rationale: Rifampin causes harmless orange-red discoloration of all body secretions (urine, tears, saliva, sweat). Patients should be warned before starting therapy. It can permanently stain soft contact lenses. This is not a sign of toxicity. (Katzung's Pharmacology)
Q73. Bedaquiline, used in MDR-TB treatment, works by:
  • A) Inhibiting cell wall synthesis (arabinosyl transferase)
  • B) Inhibiting mycobacterial ATP synthase
  • C) Disrupting mycobacterial cell membrane
  • D) Inhibiting RNA polymerase
Answer: B - Inhibiting mycobacterial ATP synthase Rationale: Bedaquiline specifically inhibits mycobacterial F1F0-ATP synthase, blocking energy production. It is bactericidal against M. tuberculosis including MDR strains. QT prolongation monitoring is required (black box warning). (Katzung's Pharmacology)
Q74. A TB patient develops acute liver failure while on first-line therapy. Which drug is most likely responsible?
  • A) Ethambutol
  • B) Isoniazid, Rifampin, or Pyrazinamide (all are hepatotoxic)
  • C) Streptomycin
  • D) Cycloserine
Answer: B - Isoniazid, Rifampin, or Pyrazinamide (all are hepatotoxic) Rationale: All three major first-line agents (INH, Rifampin, Pyrazinamide) are hepatotoxic. INH causes hepatitis (especially in slow acetylators). Pyrazinamide is most commonly responsible for severe drug-induced liver injury in the RIPE regimen. Baseline and monthly LFT monitoring is recommended.
Q75. Directly Observed Therapy (DOT) in TB is primarily implemented to:
  • A) Reduce drug costs
  • B) Ensure medication adherence and prevent emergence of drug resistance
  • C) Speed up treatment completion
  • D) Monitor drug toxicity
Answer: B - Ensure medication adherence and prevent emergence of drug resistance Rationale: Poor adherence to TB therapy leads to incomplete treatment and selection of resistant mutants, creating MDR-TB. DOT requires a healthcare worker to observe each dose being swallowed, maximizing adherence and treatment success. (WHO TB Guidelines)

SECTION 5: PULMONARY EMBOLISM & VTE (Questions 76-90)

Q76. The most common source of pulmonary embolism is:
  • A) Upper extremity DVT
  • B) Proximal deep vein thrombosis (DVT) of the lower extremities
  • C) Atrial fibrillation
  • D) Pelvic vein thrombosis
Answer: B - Proximal deep vein thrombosis (DVT) of the lower extremities Rationale: >90% of PEs arise from proximal DVTs (iliac, femoral, popliteal veins). Calf (distal) DVTs rarely embolize directly unless they extend proximally. (Robbins Pathology; Goldman-Cecil Medicine)
Q77. The Virchow's triad predisposing to VTE consists of:
  • A) Hypercoagulability, endothelial injury, stasis
  • B) Hyperlipidemia, hypertension, hyperglycemia
  • C) Inflammation, infection, coagulation
  • D) Platelet activation, vasospasm, thrombosis
Answer: A - Hypercoagulability, endothelial injury, stasis Rationale: Virchow's triad (1856): venous stasis (immobility, cardiac failure), endothelial injury (surgery, trauma, catheters), and hypercoagulability (thrombophilias, OCP, malignancy). All three contribute to DVT/PE formation. (Robbins Pathology)
Q78. Which laboratory test has the highest negative predictive value for ruling out PE in low-probability patients?
  • A) Troponin
  • B) BNP
  • C) D-dimer
  • D) Fibrinogen
Answer: C - D-dimer Rationale: D-dimer has high sensitivity (>95%) but low specificity for PE. In low-to-moderate clinical probability patients (Wells score <4), a negative D-dimer effectively rules out PE without further imaging. High D-dimer requires CT pulmonary angiography (CTPA). (Goldman-Cecil Medicine)
Q79. The gold standard imaging test for diagnosing pulmonary embolism is:
  • A) Chest X-ray
  • B) V/Q scan
  • C) CT pulmonary angiography (CTPA)
  • D) Echocardiography
Answer: C - CT pulmonary angiography (CTPA) Rationale: CTPA is the gold standard for PE diagnosis with sensitivity ~83% and specificity ~96%. It directly visualizes clots in pulmonary arteries and can identify alternative diagnoses. V/Q scan is used when CTPA is contraindicated (contrast allergy, renal insufficiency). (Fuster's The Heart)
Q80. Anticoagulation for provoked DVT/PE (following surgery) should continue for:
  • A) 2 weeks
  • B) 3 months
  • C) 6 months
  • D) Indefinitely
Answer: B - 3 months Rationale: For provoked VTE (after surgery, immobility, or other transient risk factor), anticoagulation for 3 months is recommended. Unprovoked VTE or patients with ongoing risk factors may require extended (indefinite) anticoagulation. (Goldman-Cecil Medicine)
Q81. Which direct oral anticoagulant (DOAC) is a direct Factor Xa inhibitor used for VTE treatment?
  • A) Dabigatran (direct thrombin inhibitor)
  • B) Rivaroxaban
  • C) Warfarin
  • D) Heparin
Answer: B - Rivaroxaban Rationale: Rivaroxaban is a direct Factor Xa inhibitor (along with apixaban and edoxaban). It is FDA-approved for VTE treatment, with an initial high dose (15 mg BID for 21 days), then 20 mg daily. No routine INR monitoring required. (Katzung's Pharmacology)
Q82. Massive pulmonary embolism with hemodynamic instability (systolic BP <90 mmHg) is treated with:
  • A) IV heparin alone
  • B) Systemic thrombolysis (tPA - alteplase)
  • C) Oral anticoagulation only
  • D) Embolectomy immediately without anticoagulation
Answer: B - Systemic thrombolysis (tPA - alteplase) Rationale: Massive PE with hemodynamic compromise (shock/hypotension) is treated with systemic thrombolysis (alteplase 100 mg IV over 2 hours) if no absolute contraindications. This rapidly dissolves the clot, reduces right heart pressure, and reverses shock. Anticoagulation follows. (Fuster's The Heart; Goldman-Cecil)
Q83. Heparin-induced thrombocytopenia (HIT) Type II is caused by:
  • A) Direct platelet toxicity of heparin
  • B) IgG antibodies against the platelet factor 4 (PF4)-heparin complex, causing paradoxical thrombosis
  • C) Autoimmune destruction of megakaryocytes
  • D) Drug-induced bone marrow suppression
Answer: B - IgG antibodies against the platelet factor 4 (PF4)-heparin complex, causing paradoxical thrombosis Rationale: HIT Type II occurs 5-14 days after heparin exposure. IgG antibodies bind PF4-heparin complexes on platelet surfaces, causing FcγRIIa receptor activation, thrombocytopenia, and paradoxical thrombosis. All heparin must be stopped immediately and non-heparin anticoagulant (argatroban, fondaparinux) started.
Q84. A pregnant patient develops DVT. Which anticoagulant is safest for use?
  • A) Warfarin (Vitamin K antagonist)
  • B) Rivaroxaban (Factor Xa inhibitor)
  • C) Low molecular weight heparin (LMWH - enoxaparin)
  • D) Dabigatran
Answer: C - Low molecular weight heparin (LMWH - enoxaparin) Rationale: LMWH does not cross the placenta and is safe in all trimesters. Warfarin is teratogenic (warfarin embryopathy in first trimester) and can cause fetal hemorrhage. DOACs (rivaroxaban, dabigatran) are contraindicated in pregnancy due to insufficient safety data.
Q85. The Wells score for PE risk assessment includes which of the following clinical criteria?
  • A) BNP level and troponin
  • B) Clinical signs of DVT, heart rate >100, previous DVT/PE, immobilization/surgery, malignancy, alternative diagnosis less likely, hemoptysis
  • C) Age, gender, and smoking history only
  • D) ECG findings and echo results
Answer: B - Clinical signs of DVT, heart rate >100, previous DVT/PE, immobilization/surgery, malignancy, alternative diagnosis less likely, hemoptysis Rationale: The Wells PE scoring system uses 7 clinical criteria each scoring 1-3 points. Score <2 = low probability, 2-6 = moderate, >6 = high. Low probability + negative D-dimer = PE excluded. High probability warrants direct CT-PA. (Goldman-Cecil Medicine)
Q86. The ECG finding MOST associated with massive PE is:
  • A) ST elevation in V1-V4
  • B) S1Q3T3 pattern (prominent S in I, Q wave and T wave inversion in III)
  • C) Atrial fibrillation with slow ventricular rate
  • D) Complete heart block
Answer: B - S1Q3T3 pattern (prominent S in I, Q wave and T wave inversion in III) Rationale: S1Q3T3 is a classic PE ECG finding indicating right heart strain. However, it is neither sensitive (~20%) nor specific. The most common ECG changes are sinus tachycardia and non-specific ST/T changes. Right bundle branch block and P-pulmonale are also seen.
Q87. Fondaparinux differs from LMWH in that fondaparinux:
  • A) Directly inhibits thrombin
  • B) Is a synthetic pentasaccharide that selectively inhibits Factor Xa via antithrombin III only
  • C) Can be reversed by protamine sulfate
  • D) Is extracted from porcine intestinal mucosa
Answer: B - Is a synthetic pentasaccharide that selectively inhibits Factor Xa via antithrombin III only Rationale: Fondaparinux is a synthetic pentasaccharide that binds antithrombin III, accelerating its inhibition of Factor Xa only (not thrombin). It does NOT cross-react with HIT antibodies. Protamine sulfate does NOT reverse fondaparinux. (Katzung's Pharmacology)
Q88. Warfarin's anticoagulant effect is due to:
  • A) Direct inhibition of thrombin
  • B) Inhibition of Vitamin K epoxide reductase, reducing synthesis of factors II, VII, IX, X, and proteins C and S
  • C) Activation of antithrombin III
  • D) Inhibition of Factor Xa
Answer: B - Inhibition of Vitamin K epoxide reductase, reducing synthesis of factors II, VII, IX, X, and proteins C and S Rationale: Warfarin blocks the conversion of Vitamin K epoxide back to its active reduced form, preventing gamma-carboxylation of clotting factors II, VII, IX, X (and anticoagulant proteins C and S). Factor VII has shortest half-life (6h), explaining early PT prolongation. (Katzung's Pharmacology)
Q89. Which reversal agent is used for unfractionated heparin (UFH) overdose?
  • A) Vitamin K
  • B) Idarucizumab
  • C) Protamine sulfate
  • D) Andexanet alfa
Answer: C - Protamine sulfate Rationale: Protamine sulfate (positively charged) binds and neutralizes heparin (negatively charged) 1:1 by weight. 1 mg protamine neutralizes ~100 units of UFH. Protamine only partially reverses LMWH (~60-80%). Andexanet alfa reverses Factor Xa inhibitors; idarucizumab reverses dabigatran. (Katzung's Pharmacology)
Q90. Chronic thromboembolic pulmonary hypertension (CTEPH) following PE is treated with:
  • A) Warfarin alone indefinitely
  • B) Pulmonary endarterectomy (PEA) + lifelong anticoagulation
  • C) Calcium channel blockers
  • D) Beta-blockers
Answer: B - Pulmonary endarterectomy (PEA) + lifelong anticoagulation Rationale: CTEPH (Group 4 PH) is the only potentially curable form of pulmonary hypertension. Surgical PEA removes organized thrombus from pulmonary arteries. Riociguat (sGC stimulator) is approved for inoperable CTEPH. Lifelong anticoagulation prevents recurrence. (Goldman-Cecil Medicine)

SECTION 6: LUNG CANCER (Questions 91-100)

Q91. The most common type of lung cancer in NON-SMOKERS is:
  • A) Squamous cell carcinoma
  • B) Small cell lung cancer (SCLC)
  • C) Adenocarcinoma
  • D) Large cell carcinoma
Answer: C - Adenocarcinoma Rationale: Adenocarcinoma is the most common lung cancer overall and the most common in non-smokers, women, and those under 45. It typically occurs peripherally, is associated with EGFR, ALK, ROS1 mutations, and presents as a peripheral mass/ground-glass opacity. (Goldman-Cecil Medicine)
Q92. Pancoast (superior sulcus) tumor is associated with:
  • A) Horner syndrome (ptosis, miosis, anhidrosis) + shoulder/arm pain + hand muscle wasting
  • B) Facial swelling and arm edema (superior vena cava syndrome)
  • C) Phrenic nerve palsy
  • D) Hoarseness (left recurrent laryngeal nerve involvement)
Answer: A - Horner syndrome (ptosis, miosis, anhidrosis) + shoulder/arm pain + hand muscle wasting Rationale: Pancoast tumor is an apical lung cancer invading the superior thoracic inlet. It damages the brachial plexus (shoulder/arm pain, wasting of hand muscles) and sympathetic chain (Horner syndrome: ptosis, miosis, anhidrosis). (Goldman-Cecil Medicine)
Q93. SIADH (syndrome of inappropriate ADH secretion) as a paraneoplastic syndrome is MOST commonly associated with:
  • A) Adenocarcinoma
  • B) Squamous cell carcinoma
  • C) Small cell lung cancer (SCLC)
  • D) Carcinoid tumor
Answer: C - Small cell lung cancer (SCLC) Rationale: SCLC is a neuroendocrine tumor that produces ectopic peptides. Paraneoplastic syndromes: SIADH (ectopic ADH), Cushing syndrome (ectopic ACTH), Lambert-Eaton myasthenic syndrome (anti-VGCC antibodies). Squamous cell CA causes hypercalcemia (PTHrP). (Goldman-Cecil Medicine)
Q94. First-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) is:
  • A) Platinum-based doublet chemotherapy
  • B) EGFR tyrosine kinase inhibitor (e.g., osimertinib, erlotinib, gefitinib)
  • C) Immune checkpoint inhibitor (pembrolizumab) alone
  • D) Surgery + adjuvant chemotherapy
Answer: B - EGFR tyrosine kinase inhibitor (e.g., osimertinib, erlotinib, gefitinib) Rationale: Patients with EGFR-mutated advanced NSCLC benefit significantly from EGFR TKIs. Osimertinib (3rd generation, targets T790M resistance mutation) is now preferred as first-line. These drugs target EGFR exon 19 deletions and exon 21 L858R mutations. (Fishman's Pulmonary; Goldman-Cecil)
Q95. Pembrolizumab (anti-PD-1 immune checkpoint inhibitor) is used as first-line monotherapy in NSCLC when:
  • A) EGFR or ALK mutations are present
  • B) PD-L1 tumor proportion score (TPS) ≥ 50%
  • C) PD-L1 TPS is 1-49%
  • D) KRAS mutation is present
Answer: B - PD-L1 tumor proportion score (TPS) ≥ 50% Rationale: Pembrolizumab monotherapy is indicated as first-line for stage IV NSCLC with PD-L1 TPS ≥50%, no EGFR/ALK/ROS1 mutations. For PD-L1 1-49%, pembrolizumab is combined with chemotherapy. PD-L1 testing is mandatory before therapy selection. (Fishman's Pulmonary)
Q96. The most common cause of small cell lung cancer is:
  • A) Asbestos exposure
  • B) Cigarette smoking (>90%)
  • C) Radon gas
  • D) Genetic predisposition
Answer: B - Cigarette smoking (>90%) Rationale: SCLC is almost exclusively associated with heavy cigarette smoking (>90% of cases). It is a high-grade neuroendocrine tumor with rapid growth and early metastasis. Unlike NSCLC, surgery is rarely performed; it is treated with chemotherapy + radiation. (Goldman-Cecil Medicine)
Q97. Which occupational exposure is associated with malignant mesothelioma of the pleura?
  • A) Silica dust
  • B) Asbestos (amphibole type especially)
  • C) Coal dust
  • D) Beryllium
Answer: B - Asbestos (amphibole type especially) Rationale: Malignant mesothelioma has latency of 20-40 years after asbestos exposure. Crocidolite (blue asbestos, amphibole type) is most carcinogenic. Chrysotile (serpentine type) carries lower risk. Patients present with pleural effusion and breathlessness. (Robbins Pathology)
Q98. Cisplatin + Etoposide is the standard chemotherapy regimen for:
  • A) Advanced NSCLC with EGFR mutation
  • B) Small cell lung cancer (SCLC)
  • C) ALK-rearranged NSCLC
  • D) Squamous cell carcinoma with PD-L1 > 50%
Answer: B - Small cell lung cancer (SCLC) Rationale: Cisplatin (or carboplatin) + Etoposide is the standard first-line chemotherapy for both limited and extensive SCLC. Atezolizumab (PD-L1 inhibitor) can be added to this regimen in extensive-stage SCLC. (Fishman's Pulmonary)
Q99. Superior vena cava (SVC) syndrome in lung cancer most commonly results from:
  • A) Left-sided NSCLC
  • B) Right-sided SCLC or NSCLC compressing the SVC
  • C) Metastatic pleural effusion
  • D) Pericardial tamponade
Answer: B - Right-sided SCLC or NSCLC compressing the SVC Rationale: SVC lies on the right side of the mediastinum, so right-sided tumors (especially SCLC and right-sided NSCLC) and mediastinal lymph nodes compress it. Presents with facial/arm edema, dyspnea, jugular venous distension, and dilated chest wall veins.
Q100. Lambert-Eaton myasthenic syndrome (LEMS) as a paraneoplastic complication of SCLC involves autoantibodies against:
  • A) Acetylcholine receptors
  • B) Voltage-gated calcium channels (VGCC) at presynaptic nerve terminals
  • C) Acetylcholinesterase
  • D) Voltage-gated sodium channels
Answer: B - Voltage-gated calcium channels (VGCC) at presynaptic nerve terminals Rationale: In LEMS, anti-VGCC IgG antibodies reduce Ca2+-dependent ACh vesicle release at the neuromuscular junction. Unlike myasthenia gravis, LEMS shows proximal muscle weakness that IMPROVES with repetitive stimulation (decremental response at low frequency, incremental at high frequency). (Goldman-Cecil Medicine)

SECTION 7: PULMONARY HYPERTENSION & INTERSTITIAL LUNG DISEASE (Questions 101-115)

Q101. Pulmonary arterial hypertension (PAH) is defined hemodynamically as:
  • A) Mean pulmonary artery pressure (mPAP) ≥ 20 mmHg at rest on right heart catheterization
  • B) Systolic BP > 140/90 mmHg
  • C) PCWP > 15 mmHg
  • D) mPAP > 40 mmHg
Answer: A - Mean pulmonary artery pressure (mPAP) ≥ 20 mmHg at rest on right heart catheterization Rationale: Updated 2018 World Symposium on PH changed PAH definition from mPAP ≥25 to ≥20 mmHg. PAH (Group 1) requires mPAP ≥20 mmHg + PCWP ≤15 mmHg + PVR ≥3 Wood units to distinguish from left heart disease (Group 2).
Q102. Sildenafil (PDE-5 inhibitor) treats PAH by which mechanism?
  • A) Inhibiting endothelin-1 receptors
  • B) Inhibiting PDE-5, increasing cGMP, causing pulmonary vasodilation
  • C) Activating prostacyclin receptors
  • D) Blocking calcium channels in pulmonary arteries
Answer: B - Inhibiting PDE-5, increasing cGMP, causing pulmonary vasodilation Rationale: Sildenafil inhibits PDE-5, preventing cGMP breakdown in pulmonary vascular smooth muscle. Elevated cGMP mediates vasodilation via NO/cGMP pathway. It is an approved oral therapy for PAH (WHO Group 1). Tadalafil is the once-daily PDE-5 inhibitor used in PAH.
Q103. Bosentan and macitentan are used in PAH. Their mechanism is:
  • A) PDE-5 inhibition
  • B) Endothelin receptor antagonism (ERA) - blocks ET-1's vasoconstriction and mitogenic effects
  • C) Prostacyclin receptor agonism
  • D) sGC stimulation
Answer: B - Endothelin receptor antagonism (ERA) - blocks ET-1's vasoconstriction and mitogenic effects Rationale: Bosentan (nonselective ETA/ETB antagonist) and macitentan (nonselective) block endothelin-1 receptors, reducing pulmonary vasoconstriction and vascular remodeling. Ambrisentan is a selective ETA antagonist. ERAs require monthly LFT monitoring (hepatotoxicity risk) and are teratogenic (category X).
Q104. Epoprostenol (prostacyclin) continuous IV infusion is used in severe PAH. Its mechanism is:
  • A) Beta-2 receptor agonism
  • B) Binding IP receptors, increasing cAMP, causing vasodilation and inhibiting platelet aggregation
  • C) PDE-5 inhibition
  • D) Inhibiting calcium influx
Answer: B - Binding IP receptors, increasing cAMP, causing vasodilation and inhibiting platelet aggregation Rationale: Epoprostenol (synthetic prostacyclin/PGI2) binds IP receptors on smooth muscle, increasing cAMP via adenylyl cyclase, causing potent pulmonary and systemic vasodilation plus antiplatelet effects. It has very short half-life (2-5 min), requiring continuous central IV infusion. Abrupt discontinuation is fatal.
Q105. The most common cause of idiopathic pulmonary fibrosis (IPF) exacerbation and the leading reason for IPF-related mortality is:
  • A) Bacterial pneumonia
  • B) Respiratory failure due to acute exacerbation
  • C) Pulmonary embolism
  • D) Lung cancer
Answer: B - Respiratory failure due to acute exacerbation Rationale: Acute exacerbation of IPF (AE-IPF) is defined as rapid deterioration with new bilateral ground-glass opacities on HRCT. It carries >50% mortality. Progressive respiratory failure from fibrosis is the leading cause of IPF death. (Fishman's Pulmonary)
Q106. Nintedanib and pirfenidone are approved for IPF. Nintedanib's mechanism is:
  • A) Anti-inflammatory via PDE-4 inhibition
  • B) Tyrosine kinase inhibitor targeting PDGFR, VEGFR, and FGFR to reduce fibroblast proliferation
  • C) TGF-beta pathway blockade
  • D) Anti-IL-13 monoclonal antibody
Answer: B - Tyrosine kinase inhibitor targeting PDGFR, VEGFR, and FGFR to reduce fibroblast proliferation Rationale: Nintedanib is an intracellular kinase inhibitor that blocks PDGF, VEGF, and FGF signaling pathways - key mediators of fibroblast proliferation and lung fibrosis. It reduces annual FVC decline and acute exacerbations. Diarrhea is the primary side effect. (Fishman's Pulmonary)
Q107. Hypersensitivity pneumonitis (extrinsic allergic alveolitis) is caused by:
  • A) Cigarette smoke
  • B) Inhaled organic antigens (molds, bacteria, animal proteins) triggering immune-mediated alveolar inflammation
  • C) Inorganic dust (silica, asbestos)
  • D) Drug toxicity (bleomycin, amiodarone)
Answer: B - Inhaled organic antigens (molds, bacteria, animal proteins) triggering immune-mediated alveolar inflammation Rationale: Hypersensitivity pneumonitis is a Type III/IV immune reaction to repeated inhalation of organic antigens (bird proteins = "bird fancier's lung", thermophilic actinomycetes = "farmer's lung"). HRCT shows bilateral ground-glass and nodular infiltrates. Antigen avoidance is key.
Q108. Sarcoidosis is characterized by non-caseating granulomas. The classic chest X-ray finding in Stage I sarcoidosis is:
  • A) Bilateral lower lobe infiltrates
  • B) Bilateral hilar lymphadenopathy (BHL)
  • C) Upper lobe cavitation
  • D) Pleural effusion
Answer: B - Bilateral hilar lymphadenopathy (BHL) Rationale: Sarcoidosis staging: Stage 0 = normal, Stage I = BHL alone, Stage II = BHL + parenchymal infiltrates, Stage III = parenchymal infiltrates without BHL, Stage IV = pulmonary fibrosis. Serum ACE levels are elevated in ~75% of active disease. (Goldman-Cecil Medicine)
Q109. Which drug is the FIRST-LINE treatment for symptomatic sarcoidosis?
  • A) Methotrexate
  • B) Hydroxychloroquine
  • C) Systemic corticosteroids (prednisone)
  • D) Infliximab
Answer: C - Systemic corticosteroids (prednisone) Rationale: Systemic corticosteroids (prednisone 20-40 mg/day) are the cornerstone of treatment for symptomatic pulmonary sarcoidosis, hypercalcemia, cardiac, and neurologic involvement. Methotrexate/azathioprine are steroid-sparing agents for chronic disease. (Goldman-Cecil Medicine)
Q110. Amiodarone-induced pulmonary toxicity (AIPT) presents as:
  • A) Obstructive ventilatory defect
  • B) Interstitial pneumonitis with bilateral infiltrates, restrictive physiology, reduced DLCO
  • C) Pleural effusion only
  • D) Spontaneous pneumothorax
Answer: B - Interstitial pneumonitis with bilateral infiltrates, restrictive physiology, reduced DLCO Rationale: AIPT occurs in 2-7% of patients on amiodarone. It presents as interstitial pneumonitis, organizing pneumonia, or ARDS. DLCO is an early and sensitive marker of toxicity. Treatment involves stopping amiodarone and adding systemic corticosteroids. (Fishman's Pulmonary)
Q111. Mesothelioma vs pleural effusion due to lung cancer: which investigation distinguishes them?
  • A) Chest X-ray appearance alone
  • B) Pleural biopsy with histology + immunohistochemistry (calretinin+, WT1+ for mesothelioma)
  • C) D-dimer level
  • D) CT-guided fine needle aspiration cytology alone
Answer: B - Pleural biopsy with histology + immunohistochemistry (calretinin+, WT1+ for mesothelioma) Rationale: Malignant mesothelioma expresses calretinin, WT1, cytokeratin 5/6, D2-40, and is negative for CEA, TTF-1, and MOC-31 (markers positive in lung adenocarcinoma). Histological confirmation is required for diagnosis.
Q112. Silicosis (occupational lung disease) results from inhalation of:
  • A) Asbestos fibers
  • B) Crystalline silica (quartz) particles < 5 microns
  • C) Coal dust
  • D) Beryllium
Answer: B - Crystalline silica (quartz) particles < 5 microns Rationale: Silicosis is caused by free crystalline silica (SiO2) inhalation in miners, quarry workers, and sandblasters. Macrophages cannot digest silica particles, releasing pro-fibrotic cytokines. Classic finding: "eggshell" calcification of hilar lymph nodes. Increased TB risk. (Goldman-Cecil Medicine)
Q113. Coal workers' pneumoconiosis (CWP) shows which pathological finding in the lung?
  • A) Ferruginous bodies
  • B) Progressive massive fibrosis with black coal macules and nodules
  • C) Caseating granulomas
  • D) Diffuse alveolar damage
Answer: B - Progressive massive fibrosis with black coal macules and nodules Rationale: CWP starts as coal macules (2-5mm black spots) in upper lobes. Progressive massive fibrosis (PMF, lesions >1cm) develops with advanced exposure. Caplan syndrome = CWP + rheumatoid arthritis with large bilateral lung nodules. (Robbins Pathology)
Q114. Berylliosis (chronic beryllium disease, CBD) resembles which disease histologically?
  • A) Asbestosis
  • B) Sarcoidosis (non-caseating granulomas)
  • C) Silicosis
  • D) Hypersensitivity pneumonitis
Answer: B - Sarcoidosis (non-caseating granulomas) Rationale: CBD causes non-caseating granulomatous inflammation identical to sarcoidosis histologically. It is distinguished by occupational history (aerospace, nuclear, ceramics industries) and beryllium lymphocyte proliferation test (BeLPT). (Goldman-Cecil Medicine)
Q115. Riociguat (sGC stimulator) is approved for which types of pulmonary hypertension?
  • A) PAH (Group 1) and CTEPH (Group 4)
  • B) Left heart disease-related PH (Group 2) only
  • C) Hypoxic lung disease-related PH (Group 3)
  • D) PAH only
Answer: A - PAH (Group 1) and CTEPH (Group 4) Rationale: Riociguat is a soluble guanylate cyclase (sGC) stimulator that increases cGMP independent of NO. It is the first drug approved for both PAH and inoperable/residual CTEPH. It is contraindicated with PDE-5 inhibitors and nitrates. (Katzung's Pharmacology)

SECTION 8: CYSTIC FIBROSIS, RESPIRATORY PHYSIOLOGY & OTHER (Questions 116-135)

Q116. Cystic fibrosis (CF) is caused by mutations in which gene?
  • A) CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene on chromosome 7
  • B) Alpha-1 antitrypsin gene on chromosome 14
  • C) EGFR gene on chromosome 7
  • D) BMPR2 gene on chromosome 2
Answer: A - CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene on chromosome 7 Rationale: CF is autosomal recessive. CFTR encodes a chloride channel. The most common mutation is F508del (deletion of phenylalanine at position 508). Defective chloride secretion leads to thickened secretions in lungs, pancreas, and other organs. (Robbins Pathology)
Q117. Ivacaftor is a CFTR potentiator used in CF. It works by:
  • A) Correcting CFTR protein folding (F508del mutation)
  • B) Keeping the mutant CFTR channel open longer (for gating mutations, e.g., G551D)
  • C) Replacing the defective CFTR gene
  • D) Reducing mucus viscosity
Answer: B - Keeping the mutant CFTR channel open longer (for gating mutations, e.g., G551D) Rationale: Ivacaftor is a "potentiator" that increases the gating (open probability) of CFTR channels already present on the cell surface. It is effective for gating mutations (G551D, ~4-5% of CF patients) but NOT for F508del (most common mutation), which requires a corrector (lumacaftor/tezacaftor) plus ivacaftor. (Katzung's Pharmacology)
Q118. Elexacaftor/tezacaftor/ivacaftor (Trikafta) is effective in CF patients with:
  • A) Gating mutations (G551D) only
  • B) At least one F508del allele (most CF patients - ~90%)
  • C) Only class I nonsense mutations
  • D) All CF mutations regardless of type
Answer: B - At least one F508del allele (most CF patients - ~90%) Rationale: The triple combination Elexacaftor/Tezacaftor/Ivacaftor (ETI/Trikafta) includes two CFTR correctors + one potentiator and is approved for patients ≥6 years with at least one F508del allele (~90% of CF patients). It dramatically improves FEV1, reduces exacerbations, and improves quality of life.
Q119. The normal FEV1/FVC ratio in healthy adults is:
  • A) > 0.50
  • B) > 0.60
  • C) > 0.70
  • D) > 0.80
Answer: C - > 0.70 Rationale: The FEV1/FVC ratio (Tiffeneau index) is normally >0.70 (70%) in adults. Values below 0.70 post-bronchodilator indicate obstructive ventilatory defect. The ratio decreases with age normally. (Costanzo Physiology; GOLD Guidelines)
Q120. The anatomical dead space is primarily composed of:
  • A) Alveoli that are perfused but not ventilated
  • B) Conducting airways (trachea, bronchi, bronchioles) that conduct but do not participate in gas exchange
  • C) Alveoli that are ventilated but not perfused
  • D) Pleural space
Answer: B - Conducting airways (trachea, bronchi, bronchioles) that conduct but do not participate in gas exchange Rationale: Anatomical dead space (~150 mL in adults) includes all conducting airways down to terminal bronchioles. These conduct airflow but do not participate in gas exchange. Alveolar dead space (ventilated but unperfused alveoli) forms physiological dead space with anatomical dead space. (Costanzo Physiology)
Q121. In respiratory acidosis, the kidneys compensate by:
  • A) Increasing ventilation to blow off CO2
  • B) Retaining bicarbonate (HCO3-) and excreting H+ ions
  • C) Retaining Cl- and excreting HCO3-
  • D) Increasing aldosterone secretion
Answer: B - Retaining bicarbonate (HCO3-) and excreting H+ ions Rationale: In acute respiratory acidosis (elevated PaCO2, low pH), immediate chemical buffering occurs. Chronic respiratory acidosis triggers renal compensation: increased H+ excretion (as NH4+ and titratable acid) and increased HCO3- reabsorption. Each 10 mmHg rise in PaCO2 raises HCO3- by ~1 mEq/L (acute) or ~3.5 mEq/L (chronic). (Costanzo Physiology)
Q122. The oxygen-hemoglobin dissociation curve shifts RIGHT (reduced O2 affinity, increased O2 release to tissues) due to:
  • A) Increased pH (alkalosis), decreased pCO2
  • B) Decreased 2,3-DPG, decreased temperature
  • C) Decreased pH (acidosis), increased pCO2, increased temperature, increased 2,3-DPG
  • D) Carbon monoxide binding to hemoglobin
Answer: C - Decreased pH (acidosis), increased pCO2, increased temperature, increased 2,3-DPG Rationale: Right shift of the oxyhemoglobin curve (Bohr effect) = decreased O2 affinity. Occurs in tissues during exercise/metabolic activity: acidosis, high CO2, high temperature, high 2,3-DPG. This facilitates O2 delivery to working tissues. (Costanzo Physiology)
Q123. Obstructive sleep apnea (OSA) is confirmed by which finding on polysomnography?
  • A) Apnea-hypopnea index (AHI) ≥ 5 events/hour with symptoms, or AHI ≥ 15 regardless of symptoms
  • B) Oxygen saturation < 90% for >5% of sleep time
  • C) >5 central apnea events per hour
  • D) Periodic limb movements of sleep
Answer: A - Apnea-hypopnea index (AHI) ≥ 5 events/hour with symptoms, or AHI ≥ 15 regardless of symptoms Rationale: OSA diagnosis: AHI ≥5/hour with sleepiness/symptoms, or AHI ≥15/hour regardless of symptoms. AHI = number of apneas + hypopneas per sleep hour. Severity: mild 5-15, moderate 15-30, severe >30. First-line treatment is CPAP.
Q124. Continuous Positive Airway Pressure (CPAP) treats OSA primarily by:
  • A) Improving lung compliance
  • B) Pneumatically splinting the upper airway, preventing pharyngeal collapse
  • C) Stimulating respiratory drive
  • D) Reducing apnea via improved oxygenation
Answer: B - Pneumatically splinting the upper airway, preventing pharyngeal collapse Rationale: CPAP delivers a continuous pressurized airflow that acts as a pneumatic stent, maintaining upper airway patency throughout the respiratory cycle. It eliminates apneas, reduces arousals, improves sleep quality, and reduces cardiovascular risk in OSA.
Q125. Pleural effusion exudate vs. transudate: which criterion is used in Light's criteria?
  • A) Pleural fluid LDH alone
  • B) Pleural:serum LDH ratio >0.6, pleural:serum protein ratio >0.5, or pleural LDH >2/3 upper normal serum LDH
  • C) Pleural fluid glucose < 60 mg/dL
  • D) Pleural fluid pH < 7.2
Answer: B - Pleural:serum LDH ratio >0.6, pleural:serum protein ratio >0.5, or pleural LDH >2/3 upper normal serum LDH Rationale: Light's criteria (1972) distinguish exudates from transudates: meeting ONE criterion = exudate. Exudate causes: pneumonia, malignancy, PE, TB, autoimmune disease. Transudates: heart failure, cirrhosis, nephrotic syndrome. Sensitivity 98%, specificity ~75% for exudate. (Goldman-Cecil Medicine)
Q126. Tension pneumothorax emergency management is:
  • A) Immediate chest X-ray then chest tube
  • B) Emergency needle decompression at 2nd intercostal space, midclavicular line, followed by chest tube
  • C) IV fluids and oxygen only
  • D) Endotracheal intubation first
Answer: B - Emergency needle decompression at 2nd intercostal space, midclavicular line, followed by chest tube Rationale: Tension pneumothorax (tracheal deviation, absent breath sounds, hypotension, distended neck veins) is a life-threatening emergency. Immediate needle thoracocentesis (14G needle, 2nd ICS, MCL) releases pressure WITHOUT waiting for imaging. Definitive treatment = chest tube (5th ICS, anterior axillary line).
Q127. Alpha-1 antitrypsin deficiency is diagnosed by:
  • A) FEV1/FVC ratio < 0.70
  • B) Low serum AAT level (< 20% normal) and confirmatory AAT genotyping (Pi*ZZ most common severe genotype)
  • C) BAL fluid analysis
  • D) Chest CT showing centrilobular emphysema
Answer: B - Low serum AAT level (< 20% normal) and confirmatory AAT genotyping (Pi*ZZ most common severe genotype) Rationale: AAT deficiency is confirmed by quantitative serum AAT level followed by genotyping/phenotyping. PiZZ genotype has <15% normal AAT activity, causing severe panacinar emphysema (lower lobe predominant) and liver disease. AAT augmentation therapy is available.*
Q128. Non-invasive positive pressure ventilation (NIPPV/BiPAP) is MOST beneficial in:
  • A) Acute respiratory distress syndrome (ARDS)
  • B) COPD exacerbation with acute hypercapnic respiratory failure (type II)
  • C) Post-extubation prophylaxis in surgical patients
  • D) Drowning victims
Answer: B - COPD exacerbation with acute hypercapnic respiratory failure (type II) Rationale: BiPAP reduces the need for invasive mechanical ventilation and reduces mortality in COPD exacerbations with hypercapnia (PaCO2 >45 mmHg) and pH < 7.35. It reduces work of breathing, improves gas exchange, and avoids intubation complications. (Goldman-Cecil Medicine)
Q129. The Berlin definition of ARDS requires which of the following criteria?
  • A) PaO2/FiO2 ratio < 300 + bilateral opacities on chest X-ray not explained by heart failure + onset within 1 week of a clinical insult
  • B) PaO2/FiO2 < 200 only
  • C) Positive blood cultures + bilateral infiltrates
  • D) Normal PCWP + opacities on CT only
Answer: A - PaO2/FiO2 ratio < 300 + bilateral opacities on chest X-ray not explained by heart failure + onset within 1 week of a clinical insult Rationale: Berlin 2012 ARDS criteria: (1) onset within 1 week, (2) bilateral opacities not explained by effusions/atelectasis/nodules, (3) respiratory failure not fully explained by heart failure, (4) PaO2/FiO2 <300 on ≥5 cmH2O PEEP. Mild: 200-300, Moderate: 100-200, Severe: <100.
Q130. Lung protective ventilation strategy in ARDS uses:
  • A) Tidal volume 10-15 mL/kg ideal body weight + high PEEP
  • B) Tidal volume 6 mL/kg ideal body weight + PEEP to maintain oxygenation, plateau pressure <30 cmH2O
  • C) Tidal volume 8 mL/kg + no PEEP (to minimize barotrauma)
  • D) High-frequency oscillatory ventilation only
Answer: B - Tidal volume 6 mL/kg ideal body weight + PEEP to maintain oxygenation, plateau pressure <30 cmH2O Rationale: The ARDSnet low tidal volume strategy (6 mL/kg IBW, plateau pressure <30 cmH2O) significantly reduces mortality compared to 12 mL/kg in ARDS patients. PEEP is titrated to optimize oxygenation while minimizing oxygen toxicity. Permissive hypercapnia is accepted.

SECTION 9: RESPIRATORY PHARMACOLOGY (Questions 131-150)

Q131. Dextromethorphan is an antitussive that works by:
  • A) Peripheral cough receptor suppression
  • B) Central sigma-opioid and NMDA receptor agonism, suppressing the cough center in the brainstem
  • C) Muscarinic receptor antagonism
  • D) Local anesthetic action on airway sensory nerves
Answer: B - Central sigma-opioid and NMDA receptor agonism, suppressing the cough center in the brainstem Rationale: Dextromethorphan is the D-isomer of levorphanol. It acts centrally on sigma-opioid and NMDA receptors to elevate the cough threshold without significant analgesic or dependence potential at therapeutic doses. It does NOT bind mu-opioid receptors significantly.
Q132. Codeine's antitussive effect is due to:
  • A) Direct peripheral action on airway sensory receptors
  • B) Mu-opioid receptor agonism in the brainstem cough center after hepatic conversion to morphine
  • C) Antihistamine effects
  • D) PDE-4 inhibition
Answer: B - Mu-opioid receptor agonism in the brainstem cough center after hepatic conversion to morphine Rationale: Codeine is a prodrug converted to morphine by CYP2D6. Morphine's mu-opioid receptor agonism suppresses the cough center in the medulla. CYP2D6 ultra-rapid metabolizers are at risk of morphine toxicity. Codeine is contraindicated in children post-tonsillectomy.
Q133. Acetylcysteine (NAC) is used as a mucolytic. Its mechanism of mucolysis is:
  • A) Stimulating cilia beating frequency
  • B) Breaking disulfide bonds between mucin glycoproteins, reducing mucus viscosity
  • C) Inhibiting mucus gland secretion
  • D) Alkalinizing mucus pH
Answer: B - Breaking disulfide bonds between mucin glycoproteins, reducing mucus viscosity Rationale: NAC contains a free thiol (-SH) group that reduces disulfide bridges in mucus glycoproteins, decreasing mucus viscosity. It also replenishes glutathione (antioxidant). IV NAC is the antidote for acetaminophen (paracetamol) overdose. (Fishman's Pulmonary)
Q134. Dornase alfa (DNase I) is used as a mucolytic specifically in:
  • A) COPD exacerbations
  • B) Cystic fibrosis - cleaves extracellular DNA from neutrophil breakdown in airway mucus
  • C) Post-operative atelectasis
  • D) Bronchiectasis of any cause
Answer: B - Cystic fibrosis - cleaves extracellular DNA from neutrophil breakdown in airway mucus Rationale: In CF, neutrophil-derived extracellular DNA greatly increases sputum viscosity. Dornase alfa (recombinant human DNase I) cleaves this DNA, reducing mucus viscosity. It is indicated in CF patients ≥5 years. It is inhaled via nebulizer once or twice daily.
Q135. Benralizumab, an anti-IL-5Rα monoclonal antibody for severe eosinophilic asthma, differs from mepolizumab in that:
  • A) Benralizumab blocks IL-5 binding to its receptor and also causes ADCC-mediated eosinophil depletion
  • B) Benralizumab blocks IL-5 directly in circulation
  • C) Benralizumab targets IL-4 receptor
  • D) Benralizumab is given IV only
Answer: A - Benralizumab blocks IL-5 binding to its receptor and also causes ADCC-mediated eosinophil depletion Rationale: Benralizumab binds IL-5Rα (the receptor, not IL-5 itself) and additionally recruits NK cells via FcγRIIIa, causing ADCC (antibody-dependent cell-mediated cytotoxicity) - direct eosinophil killing. This produces near-complete blood eosinophil depletion. Dosing: every 4 weeks x3, then every 8 weeks.
Q136. Which bronchodilator class is PREFERRED for COPD over asthma, due to the parasympathetic tone predominating in COPD airways?
  • A) Beta-2 agonists (SABA/LABA)
  • B) Anticholinergics (SAMA/LAMA)
  • C) Theophylline
  • D) Leukotriene antagonists
Answer: B - Anticholinergics (SAMA/LAMA) Rationale: Cholinergic (parasympathetic) tone is the dominant reversible component of airway obstruction in COPD. Therefore, anticholinergics (ipratropium, tiotropium) are particularly effective in COPD. In asthma, beta-2 agonists are preferred since beta-2 receptor-mediated bronchoconstriction is the primary mechanism.
Q137. Inhaled corticosteroids in COPD are recommended for:
  • A) All COPD patients regardless of severity
  • B) Patients with frequent exacerbations (≥2/year or 1 hospitalization), blood eosinophils ≥300 cells/μL, or asthma-COPD overlap
  • C) Patients with FEV1 > 50% only
  • D) Only patients who also have asthma
Answer: B - Patients with frequent exacerbations (≥2/year or 1 hospitalization), blood eosinophils ≥300 cells/μL, or asthma-COPD overlap Rationale: GOLD 2023 recommends ICS (as triple therapy with LABA + LAMA) for COPD patients with high exacerbation risk or elevated blood eosinophils (≥300 cells/μL). Blood eosinophil count predicts ICS responsiveness in COPD. (GOLD 2023)
Q138. Methylxanthines (theophylline, aminophylline) have which hemodynamic side effect at toxic levels?
  • A) Bradycardia and hypotension
  • B) Tachycardia, atrial and ventricular arrhythmias, and seizures
  • C) Complete heart block
  • D) Bradycardia with hypertension
Answer: B - Tachycardia, atrial and ventricular arrhythmias, and seizures Rationale: Theophylline toxicity (serum level >20 mcg/mL) causes nausea, vomiting, tachycardia, ventricular arrhythmias, hypotension, and grand mal seizures. Cardiac arrhythmias and seizures are the most dangerous manifestations. TDM is mandatory. (Katzung's Pharmacology)
Q139. Which drug for asthma/COPD can cause paradoxical bronchospasm?
  • A) Theophylline
  • B) Inhaled beta-2 agonists and inhaled anticholinergics (rarely - paradoxical bronchospasm)
  • C) Montelukast
  • D) Cromolyn sodium
Answer: B - Inhaled beta-2 agonists and inhaled anticholinergics (rarely - paradoxical bronchospasm) Rationale: Paradoxical bronchospasm can occur with both beta-2 agonists and inhaled anticholinergics - likely due to propellants, preservatives (benzalkonium chloride in ipratropium), or cold aerosol stimulating airway reflexes. It requires immediate discontinuation and alternative therapy.
Q140. Treprostinil is a prostacyclin analogue used in PAH. Its advantage over epoprostenol is:
  • A) Shorter half-life requiring more frequent dosing
  • B) Longer half-life (4 hours), allowing subcutaneous/inhaled/oral administration and no central line requirement
  • C) Greater selectivity for pulmonary circulation
  • D) It does not require any monitoring
Answer: B - Longer half-life (4 hours), allowing subcutaneous/inhaled/oral administration and no central line requirement Rationale: Treprostinil has a half-life of ~4 hours (vs epoprostenol's 2-5 minutes). This allows SC, inhaled, or oral administration, avoiding epoprostenol's need for continuous central IV infusion. Site pain with SC injection is common. (Katzung's Pharmacology)
Q141. Mucolytics in clinical practice: which agent reduces airway mucus viscosity by depolymerizing mucin polymers AND has antioxidant properties?
  • A) Guaifenesin (expectorant - increases mucus secretion)
  • B) Bromhexine
  • C) N-acetylcysteine (NAC) - cleaves disulfide bonds + antioxidant
  • D) Hypertonic saline
Answer: C - N-acetylcysteine (NAC) - cleaves disulfide bonds + antioxidant Rationale: NAC is a mucolytic AND antioxidant. Guaifenesin is an expectorant (increases mucus volume but not mucolysis). Hypertonic saline works by osmotic draw of water into airway lining fluid. Bromhexine reduces mucus production and increases mucociliary clearance.
Q142. Montelukast's pharmacokinetics: which statement is CORRECT?
  • A) It is renally excreted and dose-adjusted in renal failure
  • B) It is extensively metabolized by CYP3A4 and CYP2C9 with primarily fecal excretion
  • C) It has 100% oral bioavailability
  • D) It requires dose adjustment in hepatic impairment only when CYP2C19 activity is increased
Answer: B - It is extensively metabolized by CYP3A4 and CYP2C9 with primarily fecal excretion Rationale: Montelukast is ~65% oral bioavailability, highly protein bound (>99%), metabolized by CYP3A4/2C9, and primarily excreted in bile/feces. No renal dose adjustment is needed. Inducers (rifampin) can reduce montelukast levels significantly. (Lippincott Pharmacology)
Q143. Which inhaled drug combination (ICS + LABA) is available as a single inhaler and used in asthma and COPD?
  • A) Budesonide/formoterol (Symbicort)
  • B) Ipratropium/albuterol (Combivent) - SAMA + SABA
  • C) Tiotropium/olodaterol (Stiolto) - LAMA + LABA
  • D) Fluticasone/salmeterol (Advair) - now replaced by Fluticasone furoate/vilanterol
Answer: A - Budesonide/formoterol (Symbicort) Rationale: Budesonide/formoterol (Symbicort, Breyna) combines an ICS + LABA for both asthma and COPD. Formoterol has a rapid onset (~1-3 min) allowing this combination to also serve as a SMART (Single Maintenance And Reliever Therapy) regimen in asthma, reducing exacerbations. (Katzung's Pharmacology)
Q144. The preferred bronchodilator for acute asthma in a patient with severe cardiovascular disease (avoid tachycardia) is:
  • A) High-dose albuterol (beta-2 agonist)
  • B) Inhaled ipratropium (anticholinergic) - fewer cardiovascular side effects
  • C) IV theophylline
  • D) IV epinephrine
Answer: B - Inhaled ipratropium (anticholinergic) - fewer cardiovascular side effects Rationale: While albuterol is still first-line for acute asthma, in patients with significant cardiovascular disease where tachycardia is particularly dangerous, inhaled ipratropium is a reasonable alternative or adjunct. It has minimal cardiovascular effects at standard doses.
Q145. Phosphodiesterase-4 (PDE-4) inhibitors like roflumilast affect which inflammatory cells predominantly in COPD?
  • A) Eosinophils and mast cells
  • B) Neutrophils and macrophages
  • C) Lymphocytes only
  • D) Alveolar type II cells
Answer: B - Neutrophils and macrophages Rationale: In COPD, neutrophils and macrophages (not eosinophils as in asthma) are the predominant inflammatory cells. PDE-4 inhibition increases cAMP in these cells, reducing TNF-alpha, IL-8, and other pro-inflammatory cytokines. This is why roflumilast benefits COPD but is not approved for asthma. (Katzung's Pharmacology)
Q146. Which beta-2 agonist is considered an ultra-long-acting bronchodilator (ULABA) with 24-hour effect?
  • A) Salmeterol
  • B) Formoterol
  • C) Indacaterol
  • D) Albuterol
Answer: C - Indacaterol Rationale: Indacaterol is a once-daily ultra-long-acting beta-2 agonist with a 24-hour duration and rapid onset (5 minutes). It is approved only for COPD maintenance (not asthma). Salmeterol and formoterol are twice-daily LABAs. (Katzung's Pharmacology)
Q147. The mechanism of corticosteroid resistance in severe asthma involves:
  • A) Reduced ICS lung deposition
  • B) Reduced glucocorticoid receptor (GR) expression, impaired nuclear translocation, or histone deacetylase-2 (HDAC2) dysfunction due to oxidative stress
  • C) Increased ICS metabolism by CYP3A4
  • D) Upregulation of beta-2 receptors
Answer: B - Reduced glucocorticoid receptor (GR) expression, impaired nuclear translocation, or histone deacetylase-2 (HDAC2) dysfunction due to oxidative stress Rationale: In severe asthma and COPD, oxidative stress and cigarette smoke reduce HDAC2 activity - the enzyme normally deacetylates histones to suppress inflammatory gene expression. This causes corticosteroid resistance. Low-dose theophylline restores HDAC2 activity and ICS responsiveness.
Q148. Which drug is used in the chronic management of COPD to reduce exacerbations specifically in patients with chronic bronchitis phenotype and FEV1 < 50%?
  • A) N-acetylcysteine
  • B) Azithromycin (long-term prophylactic)
  • C) Roflumilast (PDE-4 inhibitor) specifically approved for this indication
  • D) Theophylline
Answer: C - Roflumilast (PDE-4 inhibitor) specifically approved for this indication Rationale: Roflumilast is specifically indicated as add-on to LABA/LAMA in severe COPD (FEV1 <50% predicted) with chronic bronchitis and ≥2 exacerbations/year. It reduces exacerbation frequency by ~17%. It is an anti-inflammatory oral agent, not a bronchodilator. (GOLD Guidelines; Katzung)
Q149. Capreomycin, an injectable anti-TB agent used in MDR-TB, can cause:
  • A) Optic neuritis
  • B) Nephrotoxicity and ototoxicity (vestibular and cochlear damage)
  • C) Peripheral neuropathy only
  • D) Hepatotoxicity
Answer: B - Nephrotoxicity and ototoxicity (vestibular and cochlear damage) Rationale: Capreomycin (polypeptide antibiotic from Streptomyces capreolus) is an injectable second-line TB agent. Like aminoglycosides, it causes nephrotoxicity (monitor creatinine) and ototoxicity (hearing loss, vestibular dysfunction). Baseline and serial audiometry and renal function tests are required.
Q150. A 35-year-old pharmacist is setting up a drug therapy management protocol for asthma. According to GINA 2023, the recommended "preferred reliever" for all asthma patients on ICS maintenance therapy is:
  • A) Albuterol SABA only
  • B) ICS-formoterol (low-dose) as both controller and reliever (SMART therapy or anti-inflammatory reliever)
  • C) Ipratropium as needed
  • D) Oral prednisolone
Answer: B - ICS-formoterol (low-dose) as both controller and reliever (SMART therapy or anti-inflammatory reliever) Rationale: GINA 2023 Track 1 (preferred): Recommends low-dose ICS-formoterol as the preferred reliever for all asthma patients, replacing SABA-as-needed monotherapy. Using an anti-inflammatory reliever (ICS-formoterol) rather than SABA alone reduces severe exacerbation risk because each rescue dose delivers ICS. SABA-only use increases exacerbation risk. (GINA 2023 Guidelines; Murray & Nadel's)

SUMMARY TABLE: MCQ Distribution by Topic

TopicQuestionsCount
Asthma (pharmacology & clinical)1-2525
COPD (pharmacology & clinical)26-5025
Pneumonia & Respiratory Infections51-6515
Tuberculosis Pharmacology66-7510
Pulmonary Embolism & VTE76-9015
Lung Cancer91-10010
Pulmonary Hypertension & ILD101-11515
Cystic Fibrosis, Physiology & Other116-13015
Respiratory Pharmacology131-15020
TOTAL150
Sources: Murray & Nadel's Textbook of Respiratory Medicine | Fishman's Pulmonary Diseases and Disorders | Katzung's Basic and Clinical Pharmacology (16th ed) | Goodman & Gilman's Pharmacological Basis of Therapeutics | Robbins & Cotran Pathologic Basis of Disease | Goldman-Cecil Medicine | Costanzo Physiology (7th ed) | Lippincott Illustrated Reviews Pharmacology | GOLD 2023 Guidelines | GINA 2023 Guidelines
This is a shared conversation. Sign in to Orris to start your own chat.